Yoga Versus Standard Care for Reducing Fatigue in Hispanic Cancer Survivors (YOCAS©®)
NCT05743491 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4
Last updated 2023-08-21
Summary
This is a phase II 2-arm randomized controlled trial comparing yoga (Yoga for Cancer Survivors, YOCAS©®) to standard care in reducing cancer-related fatigue in Hispanic cancer survivors. Survivors randomized to Arm 1 will receive Standard Care and Arm 2 will receive standard care plus a four-week YOCAS©® intervention where Hispanic survivors attend yoga sessions together. Investigators will acquire preliminary data on cancer-related fatigue, as well as, secondary data on other common side effects.
Conditions
Interventions
- OTHER
-
Standard Care
Cancer survivors assigned to this condition continue with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
- BEHAVIORAL
-
YOCAS©®
YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
University of Rochester
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-12
- Primary Completion
- 2023-08-16
- Completion
- 2023-08-16
Countries
- United States
Study Locations
More Related Trials
-
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
NCT00047840 ·Status: COMPLETED ·Phase: PHASE2
-
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
NCT00004011 ·Status: COMPLETED ·Phase: PHASE3
-
SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00002642 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
NCT03228186 ·Status: TERMINATED ·Phase: PHASE2
-
Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer
NCT00003692 ·Status: COMPLETED ·Phase: PHASE2
-
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
NCT00045617 ·Status: TERMINATED ·Phase: PHASE2
-
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
NCT03965234 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)
NCT01487499 ·Status: TERMINATED ·Phase: PHASE3
-
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
NCT02319889 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial
NCT05339022 ·Status: COMPLETED ·Phase: NA
-
Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
NCT05424029 ·Status: RECRUITING
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00074204 ·Status: COMPLETED ·Phase: PHASE3
-
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
NCT00254384 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00006484 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
NCT02204345 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
NCT01529112 ·Status: COMPLETED ·Phase: PHASE2
-
Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
NCT00005849 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer
NCT00003860 ·Status: COMPLETED ·Phase: PHASE2
-
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
NCT00062439 ·Status: COMPLETED ·Phase: PHASE2
-
Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00075374 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
NCT00801801 ·Status: TERMINATED ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer
NCT03348748 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide
NCT02250404 ·Status: WITHDRAWN
-
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
NCT01186861 ·Status: COMPLETED ·Phase: PHASE2
-
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
NCT02127372 ·Status: TERMINATED ·Phase: PHASE1/PHASE2